Dr. Zachariah M. Defilipp, MD

Dr. Defilipp practices at Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham.

Dr. Defilipp's NPI, 1851601264, was assigned on October 19, 2010. Dr. Defilipp holds Georgia license 006643.

Dr. Defilipp's primary practice is Massachusetts General Hospital, at 55 Fruit Street, Boston, MA 02114 in Suffolk County. The practice phone is (617) 726-2000.

Dr. Defilipp's primary practice is Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham. Dr. Defilipp is also affiliated with Brigham and Women's Hospital. The medical group on file is Massachusetts General Hospital. Dmand AI also links Dr. Defilipp to 1 more community health center, 1 home health agency and 1 medical group, each named with a free account. Dr. Defilipp's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Defilipp practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Defilipp's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Defilipp's licenses on file in 2 states: Georgia and Pennsylvania.

CMS data shows 550 Medicare services from Dr. Defilipp across 5 procedure codes in 2024, for 86 Medicare patients. Medicare paid $46,752 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 86 Medicare patients who saw Dr. Defilipp in 2024. The largest group is 65 to 74, with 48 patients. 70% of them have high blood pressure, and 70% have high cholesterol. 16% are also on Medicaid. Their average risk score is 3.98, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Defilipp's median patient age at 68, with 43% women.

In 2024, Dr. Defilipp wrote 255 Medicare Part D claims for 48 patients. 66% of them were for generic drugs. CMS names the drug for 138 of them, across 6 drugs with 11 or more claims each, at $508,244 in total drug cost. In 2023, CMS named 137 claims across 6 drugs.

Dr. Defilipp accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Defilipp as offering telehealth.

CMS Open Payments shows 27 general payments to Dr. Defilipp from 12 drug and device companies from 2021 to 2025. Consulting fees make up the largest share, 72% of the total. Sanofi and Genzyme US Companies paid the most, $24,685.